(s)-4-(3-fluoropropyl)-l-glutamic acid
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2016 (NCT02872519)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- (s)-4-(3-fluoropropyl)-l-glutamic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05501665 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2023 | National Cancer Institute (NCI), Vanderbilt University, Varian Medical Systems |
| NCT02872519 | N/A | Oct 1, 2016 | National Cancer Institute (NCI), Vanderbilt University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2016 |
| Vanderbilt University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Varian Medical Systems | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1